Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
What is your experience with in vitro chemosensitivity testing?
What instances have you used this to help guide chemotherapy selection?
Related Questions
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
What are your top takeaways from SGO 2025?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
How would you manage a patient with FIGO stage IIIB endometrial carcinoma who developed significant back pain with Carboplatin/Paclitaxel cycle 1, which worsened during cycle 2?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
How do you manage the chemotherapy portion of chemoradiation in a patient with stage IIIB (hydronephrosis) cervical cancer patient on hemodialysis?